A. Rachel Leheny net worth and biography

A. Leheny Biography and Net Worth

CEO of CalciMedica

Dr. Leheny has over 30 years of experience in the life sciences industry as a scientist, a research analyst at several investment banks and as a venture capital investor. Dr. Leheny is a Founding Managing Director for Valence Advantage Life Sciences, a venture firm based in New York. Prior to Valence, she co-founded Caxton Advantage Venture Partners, from which Valence Life Sciences emerged. Before that, she was a Senior Vice President and Head of the biotechnology research team at Lehman Brothers.

She also led the biotechnology research team at UBS Warburg. She started her biotechnology research career at Hambrecht and Quist. Dr. Leheny obtained an A.B. in Chemistry with honors from Harvard College, and a Ph.D. in chemistry from Columbia University. She did post-doctoral work at the University of California, Berkeley, where she was an NIH fellow and a lecturer.

How do I contact A. Rachel Leheny?: The corporate mailing address for Leheny and other CalciMedica executives is 505 Coast Boulevard South, Suite 307, LA Jolla, CA, 92037. CalciMedica can also be reached via phone at 858-952-5500 and via email at [email protected]. Learn More on A. Rachel Leheny's contact information.
Has A. Rachel Leheny been buying or selling shares of CalciMedica?: A. Rachel Leheny has not been actively trading shares of CalciMedica during the last ninety days. Learn More on A. Rachel Leheny's trading history.
Who are CalciMedica's active insiders?: CalciMedica's insider roster includes A. Leheny (CEO), and Eric Roberts (Insider). Learn More on CalciMedica's active insiders.
Are insiders buying or selling shares of CalciMedica?: In the last twelve months, CalciMedica insiders bought shares 1 times. They purchased a total of 49,794 shares worth more than $199,176.00. The most recent insider tranaction occured on June, 25th when Director Fred A Middleton bought 49,794 shares worth more than $199,176.00. Insiders at CalciMedica own 28.3% of the company. Learn More about insider trades at CalciMedica.
Information on this page was last updated on 6/25/2026.

A. Rachel Leheny Insider Trading History at CalciMedica

A. Rachel Leheny Buying and Selling Activity at CalciMedica

CalciMedica Company Overview

CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops CM6336, an oral CRAC channel inhibitors for chronic inflammatory indications; and Auxora, for the treatment of acute ulcerative colitis and allergic asthma. The company is based in La Jolla, California.

Today's Range

Now: $1.49

$1.42

$1.61

50 Day Range

MA: $2.60

$1.54

$5.00

2 Week Range

Now: $1.49

$1.42

$36.00

Volume

168,415 shs

Average Volume

187,870 shs

Market Capitalization

$10.18 million

P/E Ratio

N/A

Dividend Yield